



Moving to emerging efficacy data

Developing therapies to deliver patient impact





Anaveon's next generation asset has strong potential to build upon the clinical safety and efficacy that had been observed with its first generation compound."

Alex Hamilton

ANAVEON BOARD MEMBER AND SIML INVESTMENT PARTNER

HARNESSING THE POTENTIAL OF IL-2 THERAPIES

Anaveon is developing a selective IL-2 receptor agonist, a protein that could therapeutically enhance a patient's immune system to respond to tumours. In humans, IL-2 causes an immune cell, called a T-cell, to multiply and become activated. Under certain situations, T-cells can be activated to attack tumours and, as a result, IL-2 is an already approved therapy for the treatment of metastatic melanoma and renal cancer.

Anaveon's next generation compound, ANV600, is designed to overcome known challenges with IL-2 therapies. These include severe, dose-limiting side effects and a short half-life that requires frequent infusions. ANV600 could potentially have a wide therapeutic use in oncology, including in combination with cell therapies, vaccines, checkpoint inhibitors and radiotherapy.

PRE-CLINICAL DATA SUPPORTS THERAPEUTIC POTENTIAL OF ANV600

Whilst PD-1 checkpoint inhibitors have been established as the standard of care for many cancer indications, they still often result in refractory cancers (cancers that do not respond to medical treatment). During the year Anaveon presented positive pre-clinical data from ANV600, a targeted version of its first generation product ANV419, which showed encouraging efficacy signals in refractory cancer models as well as synergistic efficacy with checkpoint inhibitors. This data supports ANV600's potential as a new therapeutic in mono- and combination therapies for cancer.

INITIAL EFFICACY DATA A POTENTIAL KEY VALUE INFLECTION POINT

Anaveon is expecting to initiate its Phase I/II trial of ANV600 in H2 CY2024, with the delivery of clinical data from ANV600 in CY2026, a key value inflection point for the company. Following strategic actions taken during the year the company is now funded to this data readout which will allow it to focus on its clinical and operational execution as it approaches the clinical entry of ANV600.



2024 PORTFOLIO HIGHLIGHT

Defining a clinical strategy

During the year Anaveon took the strategic decision to focus on its next generation compound, ANV600, a targeted therapeutic which has the potential to extend the benefits of IL-2 therapies to a range of cancers. This programme builds on the company's ANV419 programme, with the potential for greater potency alongside a strong safety profile.

ANAVEON